onc Videos

Videos

Videos

Updates on the Treatment of Patients With Chronic Myelomonocytic Leukemia

10/24/2023

Featuring Eric Padron, MD

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Eric Padron, MD, discusses updates regarding managing and treating chronic myelomonocytic leukemia.

During the 2023 Lymphoma,...

10/24/2023

Lymphoma, Leukemia & Myeloma Network

Videos

Advances in Treatment Options for Patients With T-Cell Lymphoma

10/24/2023

Featuring Julie Vose, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.

At the Lymphoma, Leukemia &...

10/24/2023

Lymphoma, Leukemia & Myeloma Network

Videos

Novel Treatment Options for Patients With Myelodysplastic Syndromes

10/24/2023

Featuring Amer Zeidan, MBBS, MHS

Featuring Amer Zeidan, MBBS, MHS ...

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Amer Zeidan, MBBS, MHS, provided insights into novel treatment updates for patients with high and low-risk MDS.

During the 2023 Lymphoma,...

10/24/2023

Oncology

Videos

Novel Non-JAK-Inhibitor Therapeutic Options for Patients With Myelofibrosis

10/23/2023

Featuring Anthony Hunter, MD

Anthony Hunter, MD, Emory University, Atlanta, Georgia, explores options and the use of non-JAK-inhibitor regimens for the treatment of patients with myelofibrosis.

Anthony Hunter, MD, Emory...

10/23/2023

Oncology

Videos

Selecting a JAK Inhibitor Therapy for Patients With Myelofibrosis

10/23/2023

Featuring Anthony Hunter, MD

Anthony Hunter, MD, discusses the process of selecting and properly using a JAK-inhibitor for the treatment of patients with myelofibrosis.

Anthony Hunter, MD, discusses...

10/23/2023

Oncology

Videos

Recent Breakthroughs in Therapies for Patients With Mantle Cell Lymphoma

10/23/2023

Featuring Tycel Phillips, MD

Tycel Phillips, MD, discusses 2 recent advancements in the treatment landscape of mantle cell lymphoma, including the use of BTK inhibitor pirtobrutinib, and CAR T-cell therapy treatment lisocabtagene maraleucel.

Tycel Phillips, MD, discusses 2...

10/23/2023

Oncology

Videos

Exploring the Efficacy of BTK Inhibitor Glofitamab Among Patients With R/R MCL

10/23/2023

Featuring Tycel Phillips, MD

Tycel Phillips, MD, reports updated findings from a phase 1/2 trial examining the efficacy and safety of glofitamab, a BTK inhibitor, among patients with heavily pretreated R/R mantle cell lymphoma.

Tycel Phillips, MD, reports...

10/23/2023

Oncology

Videos

PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

10/23/2023

Featuring Nicolas Girard, MD

Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.

Prof Nicolas Girard, MD,...

10/23/2023

Oncology

Tina Cascone, MD, PhD, MD Anderson Cancer Center

Videos

Neoadjuvant Nivolumab Plus Chemotherapy Followed By Surgery and Adjuvant Nivolumab Improves EFS in NSCLC

10/23/2023

Featuring Tina Cascone, MD, PhD

Featuring Tina Cascone, MD, PhD ...

Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...

Tina Cascone, MD, PhD, discusses...

10/23/2023

Oncology

James Catto, MBChB, PhD, FRCS, University of Sheffield

Videos

Erdafitinib vs Intravesical Chemotherapy for High-Risk Non–Muscle-Invasive Bladder Cancer

10/23/2023

Featuring James Catto, MBChB, PhD, FRCS

Featuring James Catto, MBChB, PhD, FR...

Prof James Catto, MBChB, PhD, FRCS, discusses the first randomized data from Cohort 1 of the THOR-2 trial investigating erdafitinib vs intravesical chemotherapy in high-risk FGFR-altered non–muscle-invasive bladder cancer whose disease...

Prof James Catto, MBChB, PhD,...

10/23/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology